Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Arizona for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Arizona only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Arizona (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Rakesh Bagai (NPI 1114182888)

Field	Value
Entity Type	Individual
Organization	Rakesh Bagai
Address	8880 E Desert Cove Ave
City	Scottsdale
State	AZ
ZIP	85260
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	July 22, 2008

Payer Source	Total Paid
Medicare	$4.6M
Medicaid	$0

Key Findings

This provider is effectively a Medicare-only biller: lifetime Medicare revenue is $4.6M and there is no Medicaid billing on file, indicating a single-payer revenue profile concentrated entirely in fee‑for‑service Medicare. Analysts should treat Medicaid as non-contributory when modeling payer mix or network leverage for this NPI.

Revenue is highly concentrated in a small set of high-cost oncology drugs: the top three Medicare codes (J9299, J9271, J9022) are the primary drivers of income and together account for 56.4% of total Medicare revenue. Those three codes are all checkpoint/immune‑oncology agents, so changes in utilization or pricing for these agents would materially affect this provider's revenue.

The code mix and volumes point to a clinical operation centered on high-volume immunotherapy and complex infusion care consistent with a Hematology & Oncology practice: J9299 (nivolumab, $1.1M, 23.6%), J9271 (pembrolizumab, $991.3K, 22.3%) and J9022 (atezolizumab, $463.9K, 10.4%) dominate revenue, and multiple additional oncology drug codes (bevacizumab biosimilar Q5118, pemetrexed J9305, rituximab biosimilar Q5119) and supportive agents (pegfilgrastim J2506 and biosimilars Q5108/Q5111) appear throughout the top revenue list.

Several individual codes show national competitive strength for this provider: J9299 ranks #25 of 505 providers (95th percentile; notably above typical national volume), J9305 ranks #3 of 33 providers (94th percentile; notably above typical national volume), and Q5118 ranks #4 of 161 providers (98th percentile; notably above typical national volume). These ranks indicate the provider is a major national contributor for specific oncology products rather than a small-volume prescriber across the board.

Operational intensity for infusion and chemotherapy administration is unusually high: multiple administration and add‑on CPT/HCPCS codes are characterized as "extreme outlier" (for example, J2506 rank #4 of 586, 99th percentile; Q5108 rank #2 of 125, 99th percentile; 96413 rank #40 of 7514, 99th percentile; 96411 rank #2 of 1354, 100th percentile; G0498 rank #5 of 896, 100th percentile). This pattern points to a high-throughput infusion practice delivering frequent multi-agent regimens and transitional/home infusion services.

Imaging and diagnostic services are present but secondary: 78815 (fused PET/CT) generates $207.8K (4.7% of Medicare revenue) with 185 claims and ranks #1110 of 6566 providers (83th percentile; typical, unremarkable volume). The presence of PET/CT (78815, 78816) and FDG tracer A9552 suggests routine staging and treatment‑response imaging is incorporated into the care pathway, but imaging does not approach the same revenue concentration as immunotherapy drugs.

The provider makes extensive use of biosimilars and supportive care products, which is operationally and revenue‑relevant: Q5118 (bevacizumab‑bvzr) appears with $166.3K revenue and ranks #4 of 161 (98th percentile), Q5108 (pegfilgrastim‑jmdb) has $119.6K revenue and ranks #2 of 125 (99th percentile), and J2506 (pegfilgrastim, non‑biosimilar) contributes $166K and is an extreme outlier. High utilization of both originator and biosimilar growth‑factor products suggests a robust supportive‑care regimen to enable cytotoxic or immuno‑oncology treatment schedules.

The NPI tenure is long-standing: the provider was enumerated on 2008-07-22 (~18 years ago), consistent with an established oncology practice. Combined with the concentrated Medicare revenue and the pattern of high-volume specialty drug administration, this tenure supports the interpretation of a mature, procedure‑heavy Hematology & Oncology practice with national prominence for a subset of high-cost oncology agents.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

76 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9299	Injection, nivolumab, 1 mg	43,760	$20	$1.1M
J9271	Injection, pembrolizumab, 1 mg	23,600	$40	$991.3K
J9022	Injection, atezolizumab, 10 mg	7,250	$60	$463.9K
J9173	Injection, durvalumab, 10 mg	5,680	$60	$352.3K
78815	PET and CT scans are both standard imaging tools that allow doctors to evaluate the location and metabolic actions of tumors or cancer inside the body before beginning an active treatment regimen.…	190	$1,120	$207.8K
Q5118	Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg	7,560	$20	$166.3K
J2506	Injection, pegfilgrastim, excludes biosimilar, 0.5 mg	1,910	$90	$166K
J0897	Injection, denosumab, 1 mg	6,900	$20	$124.2K
Q5108	Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg	1,270	$90	$119.6K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	1,160	$100	$113.8K

Showing 1–10 of 76

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 76 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Arizona Distribution

Rakesh Bagai — 12 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Arizona

Full comparison — all codes billed, vs. state median

76 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	5	80	10,000	$40	$487.4K
J9173	1	10	5,680	$60	$352.9K
J9022	1	10	4,630	$60	$296.5K
J9299	1	30	7,480	$20	$290K
J0897	66	260	2,940	$20	$115.6K
Q5111	2	10	920	$110	$100.8K
78815	21	160	60	$710	$75.8K
Q5108	1	10	200	$90	$50.4K
Q5118	1	20	1,290	$20	$44.4K
Q5119	3	40	1,480	$20	$42.6K

Showing 1–10 of 76

Related Providers

Other providers that share a Tax Identification Number (TIN) with Rakesh Bagai, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Ironwood Physicians, PC	AZ	Hematology & Oncology Physician	$0	$7.3M
Sujith Kalmadi	AZ	Hematology & Oncology Physician	$2.2M	$0
Alice Tsai	AZ	Radiation Oncology Physician	$1.7M	$0
Charles Woo	AZ	Radiation Oncology Physician	$1.5M	$0
Ronik Bhangoo	AZ	Radiation Oncology Physician	$1.5M	$0
Pranshu Bansal	AZ	Hematology & Oncology Physician	$1.4M	$0
Murali Murty	AZ	Radiation Oncology Physician	$1.3M	$0
Luke Halbur	AZ	Hematology & Oncology Physician	$1.3M	$0
Rajesh Kukunoor	AZ	Hematology & Oncology Physician	$1.2M	$0
Robert Yoo	AZ	Hematology & Oncology Physician	$1.1M	$0

Nearby Providers

Other providers in the same ZIP code as Rakesh Bagai, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Portrush LLC	AZ	Home Health Agency	$0	$44.3M
Sunrise Native Wellness LLC	AZ	Substance Abuse Rehabilitation Facility	$0	$25.2M
Honorhealth	AZ	General Acute Care Hospital	$0	$23.8M
Pathfinders Recovery Center, LLC	AZ	Substance Use Disorder Rehabilitation Clinic/Center	$0	$20.6M
Soul Surgery LLC	AZ	Substance Abuse Rehabilitation Facility	$0	$16.4M
Sunrise Native Recovery, LLC	AZ	Substance Abuse Rehabilitation Facility	$0	$15.2M
Cornerstone Healing Center, LLC	AZ	Substance Use Disorder Rehabilitation Clinic/Center	$0	$12.4M
Embark Recovery LLC	AZ	Substance Use Disorder Rehabilitation Clinic/Center	$0	$10.9M
Neb Group Of Arizona LLC	AZ	Durable Medical Equipment & Medical Supplies	$0	$10.3M
Spooner Physical Therapy & Hand Rehab, PC	AZ	Physical Therapy Clinic/Center	$0	$8.2M

Rakesh Bagai — Billing Profile & Reimbursement Data

Sign up for Rakesh Bagai — Billing Profile & Reimbursement Data policy alerts

Rakesh Bagai — Billing Profile & Reimbursement Data

Sign up for Rakesh Bagai — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References